Comparison of advanced stage mucinous epithelial ovarian cancer and serous epithelial ovarian cancer with regard to chemosensitivity and survival outcome: a matched case-control study.
10.3802/jgo.2013.24.2.160
- Author:
Emine KARABUK
1
;
M Faruk KOSE
;
Deniz HIZLI
;
Salih TASKIN
;
Burak KARADAG
;
Taner TURAN
;
Nurettin BORAN
;
Ahmet OZFUTTU
;
U Firat ORTAC
Author Information
1. Department of Gynecologic Oncology, Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, Ankara, Turkey.
- Publication Type:Original Article
- Keywords:
Chemosensitivity;
Mucinous epithelial ovarian cancer;
Serous epithelial ovarian cancer;
Survival
- MeSH:
Case-Control Studies;
Disease-Free Survival;
Female;
Humans;
Lymph Nodes;
Mucins;
Neoplasm Metastasis;
Neoplasms, Glandular and Epithelial;
Ovarian Neoplasms;
Platinum;
Retrospective Studies
- From:Journal of Gynecologic Oncology
2013;24(2):160-166
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: The aim of this study was to compare clinicopathologic characteristics, surgery outcomes and survival outcomes of patients with stage III and IV mucinous epithelial ovarian cancer (mEOC) and serous epithelial ovarian carcinoma (sEOC). METHODS: Patients who had surgery for advanced stage (III or IV) mEOC were evaluated retrospectively and defined as the study group. Women with sEOC who were matched for age and stage of disease were randomly chosen from the database and defined as the control group. The baseline disease characteristics of patients and platinum-based chemotherapy efficacy (response rate, progression-free survival and overall survival [OS]) were compared. RESULTS: A total of 138 women were included in the study: 50 women in the mEOC group and 88 in the sEOC group. Patients in the mEOC group had significantly less grade 3 tumors and CA-125 levels and higher rate of para-aortic and pelvic lymph node metastasis. Patients in the mEOC group had significantly less platinum sensitive disease (57.9% vs. 70.8%; p=0.03) and had significantly poorer OS outcome when compared to the sEOC group (p=0.001). The risk of death for mEOC patients was significantly higher than for sEOC patients (hazard ratio, 2.14; 95% confidence interval, 1.34 to 3.42). CONCLUSION: Advanced stage mEOC patients have more platinum resistance disease and poorer survival outcome when compared to advanced stage sEOC. Therefore, novel chemotherapy strategies are warranted to improve survival outcome in patients with mEOC.
